AstraZeneca CEO Pascal Soriot vigorously defended his recently secured $23.5 million pay package, citing the UK pharma’s need to compete for talent.
“It really is about making the company competitive and attractive for my successor,” Soriot said during the company’s first-quarter earnings call with the press. “I intend to be here for a while but, of course, at some point, there will be a successor,” he added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.